MCID: CLN019
MIFTS: 55

Colonic Disease

Categories: Gastrointestinal diseases

Aliases & Classifications for Colonic Disease

MalaCards integrated aliases for Colonic Disease:

Name: Colonic Disease 12 15
Colonic Diseases 55 43 44 72
Colon Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5353
MeSH 44 D003108
UMLS 72 C0009373

Summaries for Colonic Disease

MedlinePlus : 43 Your colon, also known as the large intestine, is part of your digestive system. It's a long, hollow tube at the end of your digestive tract where your body makes and stores stool. Many disorders affect the colon's ability to work properly. Some of these include Colorectal cancer Colonic polyps - extra tissue growing in the colon that can become cancerous Ulcerative colitis - ulcers of the colon and rectum Diverticulitis - inflammation or infection of pouches in the colon Irritable bowel syndrome - an uncomfortable condition causing abdominal cramping and other symptoms Treatment for colonic diseases varies greatly depending on the disease and its severity. Treatment may involve diet, medicines and in some cases, surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Colonic Disease, also known as colonic diseases, is related to megacolon and ulcerative colitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Colonic Disease is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Bisacodyl and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include colon, testes and kidney, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 75 The large intestine, also known as the large bowel, is the last part of the gastrointestinal tract and... more...

Related Diseases for Colonic Disease

Diseases related to Colonic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 242)
# Related Disease Score Top Affiliating Genes
1 megacolon 33.1 RET EDNRB EDN3
2 ulcerative colitis 31.5 NOD2 MSH2 MLH1 CTNNB1
3 colitis 31.1 PTGS2 NOD2 MLH1 CTNNB1 AKT1
4 familial adenomatous polyposis 30.8 TP53 PTGS2 MSH2 MLH1 KRAS CTNNB1
5 adenoma 30.6 TP53 RET PTGS2 MSH2 MLH1 KRAS
6 intestinal obstruction 30.6 RET NOD2 EDNRB EDN3
7 constipation 30.5 RET EDNRB EDN3
8 endometriosis 30.4 PTGS2 MIR145 MIR143 ESR1
9 colon adenocarcinoma 30.3 PTGS2 MLH1 KRAS CTNNB1 CEACAM5 CASP3
10 colorectal adenoma 30.2 TP53 PTGS2 MSH2 MLH1 KRAS HRAS
11 hyperplastic polyposis syndrome 30.2 TP53 KRAS
12 adenocarcinoma 30.0 TP53 RET PTGS2 MLH1 KRAS HRAS
13 colorectal adenocarcinoma 29.8 TP53 PTGS2 MSH2 MLH1 KRAS HRAS
14 pancreatic cancer 29.6 TP53 STAT3 MIR143 KRAS HRAS CTNNB1
15 large intestine cancer 29.5 TP53 STAT3 PTGS2 MSH2 MLH1 KRAS
16 ovarian cancer 29.4 TP53 STAT3 MSH2 MLH1 MIR145 MIR143
17 gastrointestinal system disease 29.4 TP53 STAT3 PTGS2 NOD2 MSH2 MLH1
18 colorectal cancer 29.2 TP53 STAT3 RET PTGS2 MSH2 MLH1
19 intestinal disease 29.0 TP53 STAT3 PTGS2 NOD2 MSH2 MLH1
20 breast cancer 28.6 TP53 STAT3 PTGS2 MSH2 MLH1 MIR145
21 functional colonic disease 12.4
22 endometrial clear cell adenocarcinoma 11.0 ESR1 CTSD
23 diverticulitis of colon 11.0
24 gastric adenosquamous carcinoma 10.9 TP53 STAT3 DDX53
25 female reproductive endometrioid cancer 10.9 TP53 ESR1 CTNNB1
26 sebaceous adenoma 10.9 MSH2 MLH1 ESR1
27 male reproductive system disease 10.9 TP53 CASP3 AKT1
28 nasal cavity adenocarcinoma 10.9 TP53 KRAS HRAS
29 adult hepatocellular carcinoma 10.9 TP53 CTNNB1
30 rare adenocarcinoma of the breast 10.9 TP53 KRAS AKT1
31 appendix carcinoid tumor 10.9 MSH2 MLH1
32 sigmoid neoplasm 10.9 KRAS HRAS CEACAM5
33 lower lip cancer 10.9 MSH2 MLH1 CASP3
34 liver angiosarcoma 10.9 TP53 KRAS HRAS
35 ampulla of vater cancer 10.8 TP53 KRAS HRAS
36 apocrine adenoma 10.8 KRAS HRAS CEACAM5
37 anal squamous cell carcinoma 10.8 TP53 MLH1 AKT1
38 melanocytic nevus syndrome, congenital 10.8 MSH2 MLH1 HRAS
39 aggressive digital papillary adenocarcinoma 10.8 KRAS HRAS CEACAM5
40 adenosquamous lung carcinoma 10.8 RET KRAS HRAS
41 lung benign neoplasm 10.8 TP53 KRAS HRAS
42 colorectal cancer, hereditary nonpolyposis, type 7 10.8 MSH2 MLH1
43 keratoacanthoma 10.8 TP53 MSH2 MLH1
44 barrett's adenocarcinoma 10.8 TP53 PTGS2 KRAS
45 cervical adenocarcinoma 10.8 TP53 PTGS2 ESR1
46 breast ductal carcinoma 10.8 TP53 ESR1 CTSD CTNNB1
47 prostate squamous cell carcinoma 10.8 TP53 HRAS CEACAM5
48 adenosquamous gallbladder carcinoma 10.8 CTSD CEACAM5
49 mismatch repair cancer syndrome 10.8 MSH2 MLH1 CTNNB1
50 skin benign neoplasm 10.8 MSH2 MLH1 HRAS

Graphical network of the top 20 diseases related to Colonic Disease:



Diseases related to Colonic Disease

Symptoms & Phenotypes for Colonic Disease

UMLS symptoms related to Colonic Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Colonic Disease according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.05 HRAS KRAS
2 Decreased viability GR00106-A-0 10.05 KRAS
3 Decreased viability GR00221-A-1 10.05 AKT1 ESR1 HRAS KRAS RET
4 Decreased viability GR00221-A-2 10.05 AKT1 ESR1 HRAS KRAS RET
5 Decreased viability GR00221-A-3 10.05 AKT1 HRAS
6 Decreased viability GR00221-A-4 10.05 AKT1 ESR1 RET
7 Decreased viability GR00231-A 10.05 RET
8 Decreased viability GR00301-A 10.05 KRAS RET
9 Decreased viability GR00381-A-1 10.05 KRAS
10 Decreased viability GR00402-S-2 10.05 AKT1 ESR1 HRAS KRAS RET
11 Decreased cell migration GR00055-A-1 9.35 AKT1 CTNNB1 CTSD HRAS KRAS

MGI Mouse Phenotypes related to Colonic Disease:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.48 CASP3 CTNNB1 CTSD EDN3 EDNRB ESR1
2 cellular MP:0005384 10.46 AKT1 CASP3 CTNNB1 CTSD EDNRB ESR1
3 behavior/neurological MP:0005386 10.44 AKT1 CASP3 CTNNB1 CTSD EDN3 EDNRB
4 homeostasis/metabolism MP:0005376 10.43 AKT1 CASP3 CTNNB1 CTSD EDNRB ESR1
5 hematopoietic system MP:0005397 10.41 AKT1 CASP3 CTNNB1 CTSD EDNRB ESR1
6 mortality/aging MP:0010768 10.41 AKT1 CASP3 CTNNB1 CTSD EDN3 EDNRB
7 endocrine/exocrine gland MP:0005379 10.4 AKT1 CASP3 CTNNB1 CTSD EDNRB ESR1
8 growth/size/body region MP:0005378 10.4 AKT1 CASP3 CTNNB1 CTSD EDNRB ESR1
9 immune system MP:0005387 10.39 AKT1 CASP3 CTNNB1 CTSD EDNRB ESR1
10 integument MP:0010771 10.38 AKT1 CASP3 CTNNB1 CTSD EDN3 EDNRB
11 cardiovascular system MP:0005385 10.36 AKT1 CASP3 CTNNB1 EDNRB ESR1 HRAS
12 embryo MP:0005380 10.3 AKT1 CTNNB1 EDN3 EDNRB ESR1 KRAS
13 nervous system MP:0003631 10.3 AKT1 CASP3 CTNNB1 CTSD EDN3 EDNRB
14 neoplasm MP:0002006 10.26 AKT1 CTNNB1 EDNRB ESR1 HRAS KRAS
15 muscle MP:0005369 10.19 AKT1 CASP3 CTNNB1 EDNRB ESR1 KRAS
16 craniofacial MP:0005382 10.16 CASP3 CTNNB1 EDNRB HRAS KRAS STAT3
17 liver/biliary system MP:0005370 10.07 AKT1 CTNNB1 ESR1 KRAS PTGS2 STAT3
18 normal MP:0002873 10.06 AKT1 CTNNB1 ESR1 HRAS KRAS PTGS2
19 hearing/vestibular/ear MP:0005377 10.05 CASP3 CTNNB1 CTSD EDNRB KRAS TP53
20 no phenotypic analysis MP:0003012 10.03 CASP3 CTNNB1 ESR1 HRAS KRAS PTGS2
21 renal/urinary system MP:0005367 10.02 CASP3 CTNNB1 EDNRB ESR1 HRAS KRAS
22 reproductive system MP:0005389 9.96 AKT1 CASP3 CTNNB1 ESR1 KRAS MLH1
23 respiratory system MP:0005388 9.93 AKT1 CASP3 CTNNB1 EDNRB ESR1 HRAS
24 pigmentation MP:0001186 9.85 CASP3 CTNNB1 EDN3 EDNRB KRAS TP53
25 skeleton MP:0005390 9.7 AKT1 CASP3 CTNNB1 EDNRB ESR1 HRAS
26 vision/eye MP:0005391 9.28 CASP3 CTNNB1 CTSD EDNRB KRAS MLH1

Drugs & Therapeutics for Colonic Disease

Drugs for Colonic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bisacodyl Approved Phase 4 603-50-9
2
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
5
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
6
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
7
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
8
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
9 Ramosetron Investigational Phase 4 132036-88-5
10 Anti-Inflammatory Agents, Non-Steroidal Phase 4
11 Cyclooxygenase Inhibitors Phase 4
12 Fibrinolytic Agents Phase 4
13 Platelet Aggregation Inhibitors Phase 4
14 Olive Phase 4
15 Antiemetics Phase 4
16 Serotonin Antagonists Phase 4
17 Serotonin Agents Phase 4
18 Micronutrients Phase 4
19 Trace Elements Phase 4
20 Vitamins Phase 4
21 Nutrients Phase 4
22 Hormones Phase 4
23 Vitamin D2 Phase 4
24 Ergocalciferols Phase 4
25 Calciferol Phase 4
26 Calcium, Dietary Phase 4
27 Bone Density Conservation Agents Phase 4
28 Cathartics Phase 4
29 Laxatives Phase 4
30
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
31
Peppermint Approved Phase 3
32
Peppermint oil Approved, Investigational Phase 3 8006-90-4
33
Eluxadoline Approved, Investigational Phase 3 864821-90-9
34
Desipramine Approved, Investigational Phase 3 50-47-5 2995
35
Sodium sulfate Approved, Vet_approved Phase 3 7757-82-6
36
Dexmedetomidine Approved, Vet_approved Phase 3 113775-47-6 68602 5311068
37
leucovorin Approved Phase 3 58-05-9 143 6006
38
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
39
Bevacizumab Approved, Investigational Phase 3 216974-75-3
40
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
41
Budesonide Approved Phase 3 51333-22-3 63006 5281004
42
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 54670067 5785
43
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
44 Visilizumab Investigational Phase 2, Phase 3 219716-33-3
45 Parasympatholytics Phase 3
46 Antioxidants Phase 3
47 Protective Agents Phase 3
48 Anti-Bacterial Agents Phase 3
49 Immunologic Factors Phase 2, Phase 3
50 Antidepressive Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 129)
# Name Status NCT ID Phase Drugs
1 Multidisciplinary Approach Versus Conventional Approach in Colonic Preparation of Hospitalized Patients. A Randomized Controlled Trial Unknown status NCT01853709 Phase 4 Polyethylene glycol (PEG);Bisacodyl
2 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
3 Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the Co-primary Endpoint in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT00918411 Phase 4 Ramosetron;Placebo
4 Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - Double-blind, Parallel-group Comparative Study in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT01225237 Phase 4 Ramosetron;Placebo
5 Endoscopic Detection of Small Bowel Dysplasia and Cancer in Patients With Jejuna or Ileal Crohn Disease : Prospective Study in a Cohort of High Risk Patients Completed NCT01180452 Phase 4
6 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease: a Placebo-controlled Randomized Trial Completed NCT02010762 Phase 4 Vitamin D;Placebo
7 A Randomized Clinical Trial Comparing Standard and Invidualized Bowel Preparation for Colonoscopy Recruiting NCT03428724 Phase 4 Standard Preparation;Individualized Preparation
8 Continuous Ketamine Infusion Versus Placebo in the Treatment of Acute Post-Surgical Pain: A Randomized Trial Evaluating the Efficacy of Ketamine in Colorectal Surgery Withdrawn NCT02785003 Phase 4 Placebo;Ketamine;Acetaminophen;Opioid;Alvimopan
9 Evaluation of PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon Completed NCT00604162 Phase 3
10 Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) Night Procedure Completed NCT00951587 Phase 3
11 Evaluation of PillCam™ Colon 2 in Visualization of the Colon Completed NCT01063231 Phase 3
12 A Prospective, Randomized, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of PBK-1701TC Completed NCT03509220 Phase 3 PBK-1701TC;Standard oral preparation
13 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome Completed NCT01553747 Phase 3 Eluxadoline;Placebo
14 Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery Completed NCT02716285 Phase 3 Ileocolonic release peppermint oil;Placebo;Small intestinal release peppermint oil
15 Multicenter Trial of Functional Bowel Disorders Completed NCT00006157 Phase 3 Desipramine
16 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2 mg/25 mL BID for 2 Weeks, Followed by 2 mg/25 mL QD for 4 Weeks) Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis Completed NCT01008423 Phase 3 Budesonide;Placebo
17 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2 mg/25 mL BID for 2 Weeks, Followed by 2 mg/25 mL QD for 4 Weeks) Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis Completed NCT01008410 Phase 3 Budesonide;Placebo
18 A Prospective, Randomized, Single-blinded (Evaluator), 3-treatment Arm, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of CDFR0612 and CDFR0613 Completed NCT02304523 Phase 3 CDFR0612;CDFR0613;Coolprep Powder
19 A Phase I, Dose-Escalation, Pilot Study of Visilizumab in Patients With Severe Ulcerative Colitis That is Refractory to Corticosteroids Completed NCT00032305 Phase 2, Phase 3 Visilizumab
20 Phase III Study to Evaluate the Effect of 10% Metronidazole Ointment, Applied Topically Three Times a Day in and Around the Anus and the Change in Perianal Crohn's Disease Activity Completed NCT00509639 Phase 3 10% Metronidazole Ointment
21 Randomized Clinical Trial on the Efficacy of an Adapted Bowel Preparation for Diabetic Patients Undergoing a Colonoscopy. DIMEPREP Study Completed NCT02300779 Phase 3
22 Improvement of Tolerability for Bowel Preparation for Colonoscopy in Diabetic Patients. A Randomized Controlled Trial of Two Bowel Preparation Protocols Including 4 Liters PEG vs. 2 Liters PEG Plus Ascorbic Acid. iDIMEPREP Study. Completed NCT02297399 Phase 3 PEG-ascorbate 2L;PEG 4L
23 Randomised Study Comparing the Use of Propofol Versus the Use of Dexmedetomidine as a Sedative Agent for Patients Presented for Lower Gastrointestinal Endoscopy Recruiting NCT03466632 Phase 3 Propofol;Dexmedetomidine
24 A Phase III Double-blind Placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Recruiting NCT03464305 Phase 3 acetylsalicylic acid;Placebo
25 A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC). Active, not recruiting NCT02753127 Phase 3 Napabucasin;Fluorouracil;Leucovorin;Irinotecan;Bevacizumab
26 A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of a 12-week Add-on Treatment With LT-02 vs. Placebo in Subjects With Ulcerative Colitis Refractory to Standard Treatment With Mesalamine Terminated NCT02849951 Phase 3 LT-02;LT-02 Placebo
27 A Phase 3, Open Label, Multicenter Study to Assess the Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis Terminated NCT01349673 Phase 3 Budesonide Foam
28 A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis Terminated NCT01016262 Phase 3 MAX-002;Placebo;Canasa®
29 Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer Unknown status NCT00201331 Phase 2 leucovorin+5-FU
30 A Randomized, Double Blind, Single Dose, Two Treatment, Two Period Crossover Pharmacokinetic Study Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®) in Healthy Volunteers Completed NCT02291445 Phase 2 Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule);Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)
31 A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea Completed NCT01130272 Phase 2 JNJ-27018966;Placebo
32 Phase II Study of YM060 - Double-blind, Parallel-group Comparative Study in Patients (Female) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT01274000 Phase 2 YM060;placebo
33 The Effect of Kyo-Dophilus 1.5 Billion on the Symptoms of Severe Irritable Bowel Syndrome Completed NCT01887834 Phase 1, Phase 2
34 Randomised, Controlled Trial of Intravenous Saline Pre-hydration in Patients Undergoing Outpatient Colonoscopy Completed NCT00308152 Phase 2 Infusion of 1 litre of normal saline before colonoscopy
35 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of TRN 002 (Crofelemer) for the Symptomatic Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (d-IBS) Completed NCT00101725 Phase 2 crofelemer
36 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UC Completed NCT02647866 Phase 2 KHK4083;Placebo
37 The Effect of Kyo-Dophilus 1.5 Billion on the Symptoms of Irritable Bowel Syndrome (IBS) Completed NCT01176227 Phase 1, Phase 2
38 Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors Completed NCT01177007 Phase 2
39 A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy Completed NCT01926444 Phase 2 GIC-1001
40 Denosumab (A Monoclonal Antibody to Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) in Crohn's Disease Completed NCT02321280 Phase 1, Phase 2 Denosumab
41 A Phase I/II Study of Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers Recruiting NCT03332498 Phase 1, Phase 2 Pembrolizumab;Ibrutinib
42 Evaluation of the Effect of the Ocoxin®-Viusid® Nutritional Supplement on the Quality of Life of Patients With Metastatic Colorectal Adenocarcinoma. Phase II Recruiting NCT03559543 Phase 2
43 A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Recruiting NCT03037385 Phase 1, Phase 2 pralsetinib (BLU-667)
44 A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Recruiting NCT03093116 Phase 1, Phase 2 Oral repotrectinib (TPX-0005)
45 A Phase 2 Study of GVAX Colon Vaccine (With Cyclophosphamide) and Pembrolizumab in Patients With Mismatch Repair-Proficient (MMR-p) Advanced Colorectal Cancer Active, not recruiting NCT02981524 Phase 2 CY;Pembrolizumab
46 Phase I/II Study of Intravenous Ascorbic Acid in Combination With Irinotecan Versus Irinotecan Alone for Advanced Colorectal Cancer Terminated NCT01550510 Phase 1, Phase 2 Ascorbic Acid;Irinotecan
47 Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer Terminated NCT00838578 Phase 1, Phase 2 Irinotecan
48 A Phase 2 Study to Evaluate the Safety and Potential Efficacy of Clostridium Butyricum MIYAIRI 588 Strain (MIYA-BM Fine Granules) for the Prevention of Recurrent Clostridium Difficile Infections Withdrawn NCT01077245 Phase 2 MIYA-BM Fine Granules (CBM588);Placebo Fine Granules (without CBM588)
49 Phase IB With Expansion of Patients at the MTD Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Completed NCT01294826 Phase 1 AUY922;Cetuximab
50 A Double-Blind, Placebo Controlled, Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GIC-1001 in Normal Healthy Volunteers Completed NCT01738425 Phase 1 GIC-1001; 125 mg oral tablets;GIC-1001 matching placebo

Search NIH Clinical Center for Colonic Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Scopolamine
Scopolamine Hydrobromide

Cochrane evidence based reviews: colonic diseases

Genetic Tests for Colonic Disease

Anatomical Context for Colonic Disease

MalaCards organs/tissues related to Colonic Disease:

41
Colon, Testes, Kidney, Small Intestine, Liver, Brain, Bone

Publications for Colonic Disease

Articles related to Colonic Disease:

(show top 50) (show all 1153)
# Title Authors PMID Year
1
Sigmoid Volvulus. 17
31237646 2019
2
Three-Dimensional Versus Two-Dimensional Laparoscopic-Assisted Transanal Pull-Through for Hirschsprung's Disease in Children: Preliminary Results of a Prospective Cohort Study in a Tertiary Hospital. 17
30855202 2019
3
Management of acute diverticulitis. 17
30860921 2019
4
Novel NOD2 haplotype strengthens the association between TLR4 Asp299gly and Crohn's disease in an Australian population. 9 38
18213697 2008
5
Expression of receptor interacting protein 3 and mixed lineage kinase domain-like protein-key proteins in necroptosis is upregulated in ulcerative colitis. 38
31431023 2019
6
Natural history of children with mild Crohn's disease. 38
31435176 2019
7
Diffusion-weighted magnetic resonance for assessing fibrosis in Crohn's disease. 38
31392397 2019
8
Silk fibroin-based nanotherapeutics: application in the treatment of colonic diseases. 38
31290366 2019
9
The Role of Laparoscopic, Robotic, and Open Surgery in Uncomplicated and Complicated Inflammatory Bowel Disease. 38
31078253 2019
10
Small bowel capsule endoscopy in ulcerative colitis: the capcolitis study: a prospective observational study. 38
31082999 2019
11
Proteomics highlights common and distinct pathophysiological processes associated to ileal and colonic ulcers in Crohn's disease. 38
31282946 2019
12
The association between the increased performance of laparoscopic colon surgery and a reduced risk of surgical site infection. 38
30684051 2019
13
A 10-Year Follow-up Study of the Natural History of Perianal Crohn's Disease in a Danish Population-Based Inception Cohort. 38
30576474 2019
14
Group IID, IIE, IIF and III secreted phospholipase A2s. 38
30905347 2019
15
Relationship between Barrett's esophagus and colonic diseases: a role for colonoscopy in Barrett's surveillance. 38
31240437 2019
16
Microscopic/"Backwash" Ileitis and Its Association With Colonic Disease in New Onset Pediatric Ulcerative Colitis. 38
31124991 2019
17
European Society of Paediatric Radiology abdominal imaging task force: statement on imaging in very early onset inflammatory bowel disease. 38
30915515 2019
18
Antibiotic-resistant hypervirulent Klebsiella pneumoniae causing community- acquired liver abscess: an emerging disease. 38
31198568 2019
19
Right hemicolectomy: a network meta-analysis comparing open, laparoscopic-assisted, total laparoscopic, and robotic approach. 38
30456506 2019
20
Long-term outcome of pediatric-onset Crohn's disease: A population-based cohort study. 38
30611597 2019
21
Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases? 38
31009791 2019
22
No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases. 38
30529584 2019
23
Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis. 38
30914450 2019
24
Clinical and Endoscopic Management of Synchronous Amoebic Liver Abscess and Bleeding Colonic Ulcers. 38
31304698 2019
25
Role of lymph node yield and lymph node ratio in predicting outcomes in non-metastatic colorectal cancer. 38
30734020 2019
26
Entero-neovesical fistula after radical cystectomy and orthotopic ileal neobladder: A report of two cases requiring surgical management. 38
30118403 2019
27
The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors. 38
31294386 2019
28
Statin Exposure Is Not Associated with Reduced Prevalence of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease. 38
30400722 2019
29
Adverse events related to colonoscopy: Global trends and future challenges. 38
30670909 2019
30
Microscopic / "Backwash" Ileitis and its Association with Colonic Disease in New Onset Pediatric Ulcerative Colitis. 38
30676522 2019
31
Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway. 38
30626868 2019
32
Assessing intestinal permeability in Crohn's disease patients using orally administered 52Cr-EDTA. 38
30730969 2019
33
Crohn's Disease in Clinical Remission Is Marked by Systemic Oxidative Stress. 38
31080419 2019
34
Mutations in the NOD2 gene are associated with a specific phenotype and lower anti-tumor necrosis factor trough levels in Crohn's disease. 38
30284387 2018
35
Curriculum review: colorectal cancer surveillance and management of dysplasia in IBD. 38
30245789 2018
36
Risk Factors Associated With Pouch Adenomas in Patients With Familial Adenomatous Polyposis. 38
30086059 2018
37
Epidemiology and clinical course of inflammatory bowel disease in the Central Province of Sri Lanka: A hospital-based study. 38
30483577 2018
38
[Primary eosinophilic colitis in a celiac patient]. 38
29943760 2018
39
Clinical Pattern of Surgical Crohn Disease Patients. 38
30183580 2018
40
Recent Advance in Colon Capsule Endoscopy: What's New? 38
30078307 2018
41
Colonic Crohn's Disease Is Associated with Less Aggressive Disease Course Than Ileal or Ileocolonic Disease. 38
29611078 2018
42
Diffusion-weighted MRI in inflammatory bowel disease. 38
29739674 2018
43
A Case of Right-Sided Ulcerative Colitis with Mesalamine-Induced Hypersensitivity Reactions. 38
29849018 2018
44
Neonatal Presentation of Unremitting Inflammatory Bowel Disease. 38
29892152 2018
45
Clinical Implications of Pediatric Colonic Eosinophilia. 38
29095349 2018
46
A look at the smelly side of physiology: transport of short chain fatty acids. 38
29305650 2018
47
Applications of Colon Capsule Endoscopy. 38
29644509 2018
48
High prevalence of cholestasis, with increased conjugated bile acids in inflammatory bowel diseases patients. 38
29670889 2018
49
Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people. 38
29563038 2018
50
Granulomatous Upper Gastrointestinal Inflammation in Pediatric Ulcerative Colitis. 38
28991840 2018

Variations for Colonic Disease

Expression for Colonic Disease

Search GEO for disease gene expression data for Colonic Disease.

Pathways for Colonic Disease

Pathways related to Colonic Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 TP53 STAT3 RET PTGS2 NOD2 KRAS
2
Show member pathways
13.43 TP53 STAT3 RET PTGS2 NOD2 KRAS
3
Show member pathways
13.11 KRAS HRAS ESR1 EDNRB CTSD AKT1
4
Show member pathways
13.09 TP53 STAT3 KRAS HRAS CTNNB1 CASP3
5
Show member pathways
13.06 TP53 PTGS2 KRAS HRAS CTNNB1 CASP3
6
Show member pathways
13.04 TP53 STAT3 PTGS2 KRAS HRAS CTNNB1
7
Show member pathways
13.03 TP53 KRAS HRAS CTNNB1 CASP3 AKT1
8
Show member pathways
13 TP53 KRAS HRAS EDNRB EDN3 CASP3
9
Show member pathways
12.98 STAT3 PTGS2 KRAS HRAS CTNNB1 AKT1
10
Show member pathways
12.98 TP53 STAT3 PTGS2 MSH2 MLH1 KRAS
11
Show member pathways
12.89 TP53 KRAS HRAS CTSD CASP3 AKT1
12 12.84 TP53 KRAS HRAS CASP3 AKT1
13
Show member pathways
12.84 TP53 MLH1 KRAS HRAS ESR1 CTNNB1
14
Show member pathways
12.77 TP53 STAT3 KRAS HRAS ESR1 AKT1
15
Show member pathways
12.76 TP53 STAT3 KRAS HRAS CASP3 AKT1
16
Show member pathways
12.75 KRAS HRAS CTNNB1 CASP3 AKT1
17
Show member pathways
12.7 TP53 STAT3 RET MSH2 MLH1 KRAS
18
Show member pathways
12.67 TP53 STAT3 KRAS HRAS AKT1
19
Show member pathways
12.63 TP53 STAT3 MSH2 KRAS HRAS CTNNB1
20
Show member pathways
12.61 TP53 STAT3 PTGS2 KRAS HRAS ESR1
21
Show member pathways
12.54 STAT3 KRAS HRAS AKT1
22
Show member pathways
12.52 TP53 KRAS HRAS CTNNB1 CASP3 AKT1
23
Show member pathways
12.51 STAT3 KRAS HRAS ESR1 CTSD CASP3
24 12.5 TP53 STAT3 PTGS2 MIR145 MIR143 KRAS
25
Show member pathways
12.48 PTGS2 KRAS HRAS AKT1
26
Show member pathways
12.46 TP53 STAT3 HRAS AKT1
27 12.44 TP53 KRAS HRAS CTNNB1 AKT1
28
Show member pathways
12.43 STAT3 PTGS2 KRAS HRAS ESR1 CTNNB1
29
Show member pathways
12.41 STAT3 KRAS HRAS AKT1
30
Show member pathways
12.4 STAT3 PTGS2 CASP3 AKT1
31
Show member pathways
12.4 STAT3 HRAS CTNNB1 AKT1
32
Show member pathways
12.39 PTGS2 HRAS ESR1 AKT1
33
Show member pathways
12.38 TP53 PTGS2 HRAS AKT1
34 12.38 TP53 STAT3 KRAS HRAS CASP3
35
Show member pathways
12.33 STAT3 PTGS2 CASP3 AKT1
36
Show member pathways
12.32 TP53 STAT3 KRAS HRAS CASP3 AKT1
37 12.31 NOD2 CTSD CASP3 AKT1
38
Show member pathways
12.29 PTGS2 KRAS HRAS AKT1
39
Show member pathways
12.29 TP53 KRAS HRAS CASP3 AKT1
40
Show member pathways
12.28 RET KRAS HRAS AKT1
41 12.27 STAT3 KRAS HRAS AKT1
42
Show member pathways
12.26 TP53 KRAS HRAS AKT1
43 12.25 TP53 KRAS HRAS AKT1
44
Show member pathways
12.24 TP53 KRAS HRAS CASP3 AKT1
45 12.23 TP53 KRAS HRAS CASP3 AKT1
46
Show member pathways
12.22 TP53 KRAS HRAS AKT1
47
Show member pathways
12.22 STAT3 KRAS HRAS AKT1
48 12.21 STAT3 HRAS CTNNB1 CASP3 AKT1
49
Show member pathways
12.2 STAT3 HRAS CTNNB1 AKT1
50 12.19 STAT3 KRAS HRAS CTNNB1 AKT1

GO Terms for Colonic Disease

Cellular components related to Colonic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.43 TP53 PTGS2 NOD2 ESR1 CTNNB1 AKT1
2 membrane raft GO:0045121 9.02 RET KRAS EDNRB CTSD CASP3

Biological processes related to Colonic Disease according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.99 HRAS ESR1 CTNNB1 AKT1
2 response to drug GO:0042493 9.95 STAT3 RET PTGS2 CTNNB1 CASP3
3 positive regulation of protein phosphorylation GO:0001934 9.93 KRAS HRAS EDNRB AKT1
4 aging GO:0007568 9.93 STAT3 PTGS2 EDNRB AKT1
5 cell proliferation GO:0008283 9.92 TP53 STAT3 CTNNB1 AKT1
6 regulation of apoptotic process GO:0042981 9.92 TP53 NOD2 ESR1 CTNNB1 AKT1
7 neuron differentiation GO:0030182 9.86 RET EDN3 CTNNB1 CASP3
8 regulation of inflammatory response GO:0050727 9.84 PTGS2 NOD2 ESR1
9 response to organic cyclic compound GO:0014070 9.84 STAT3 PTGS2 EDNRB CASP3
10 Ras protein signal transduction GO:0007265 9.83 TP53 KRAS HRAS
11 response to glucocorticoid GO:0051384 9.83 PTGS2 KRAS CASP3
12 negative regulation of neuron death GO:1901215 9.81 STAT3 CTNNB1 AKT1
13 cytokine-mediated signaling pathway GO:0019221 9.8 TP53 STAT3 PTGS2 KRAS CASP3 AKT1
14 positive regulation of gene expression GO:0010628 9.8 TP53 STAT3 RET KRAS HRAS CTNNB1
15 neural crest cell migration GO:0001755 9.78 RET EDNRB EDN3
16 response to organic substance GO:0010033 9.76 STAT3 PTGS2 CASP3 AKT1
17 cellular response to organic cyclic compound GO:0071407 9.73 STAT3 NOD2 CASP3 AKT1
18 protein localization to chromatin GO:0071168 9.7 MSH2 ESR1
19 positive regulation of phospholipase C activity GO:0010863 9.7 HRAS ESR1
20 positive regulation of fibroblast migration GO:0010763 9.69 MIR145 AKT1
21 enteric nervous system development GO:0048484 9.68 RET EDNRB
22 regulation of mitochondrial membrane permeability GO:0046902 9.68 TP53 STAT3
23 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.68 TP53 ESR1
24 positive regulation of isotype switching to IgG isotypes GO:0048304 9.67 MSH2 MLH1
25 angiotensin-activated signaling pathway GO:0038166 9.67 MIR145 MIR143
26 positive regulation of MAP kinase activity GO:0043406 9.67 NOD2 KRAS HRAS EDN3
27 response to isolation stress GO:0035900 9.64 KRAS HRAS
28 positive regulation of isotype switching to IgA isotypes GO:0048298 9.62 MSH2 MLH1
29 aorta smooth muscle tissue morphogenesis GO:0060414 9.61 MIR145 MIR143
30 vein smooth muscle contraction GO:0014826 9.58 EDNRB EDN3
31 somatic recombination of immunoglobulin gene segments GO:0016447 9.58 MSH2 MLH1
32 striated muscle cell differentiation GO:0051146 9.58 KRAS CASP3 AKT1
33 regulation of phenotypic switching GO:1900239 9.57 MIR145 MIR143
34 negative regulation of apoptotic process GO:0043066 9.56 TP53 STAT3 PTGS2 EDNRB CTNNB1 CEACAM5
35 response to estradiol GO:0032355 9.55 STAT3 PTGS2 ESR1 CTNNB1 CASP3
36 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.51 MSH2 MLH1
37 posterior midgut development GO:0007497 9.49 RET EDNRB
38 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.48 MIR145 MIR143
39 positive regulation of cell proliferation GO:0008284 9.28 STAT3 PTGS2 NOD2 KRAS HRAS EDNRB
40 signal transduction GO:0007165 10.29 STAT3 RET KRAS HRAS ESR1 EDNRB
41 positive regulation of transcription by RNA polymerase II GO:0045944 10.19 TP53 STAT3 NOD2 HRAS ESR1 CTNNB1
42 nervous system development GO:0007399 10.08 STAT3 RET EDNRB CTNNB1 AKT1
43 cellular response to DNA damage stimulus GO:0006974 10.07 TP53 MSH2 MLH1 CASP3 AKT1
44 positive regulation of transcription, DNA-templated GO:0045893 10.07 TP53 STAT3 RET ESR1 CTNNB1 AKT1
45 negative regulation of cell proliferation GO:0008285 10.05 TP53 STAT3 PTGS2 HRAS CTNNB1
46 positive regulation of apoptotic process GO:0043065 10 TP53 PTGS2 CTNNB1 CASP3 AKT1

Molecular functions related to Colonic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.65 TP53 MSH2 MLH1 ESR1 CTNNB1
2 protein phosphatase binding GO:0019903 9.54 TP53 STAT3 CTNNB1
3 protein kinase binding GO:0019901 9.5 TP53 STAT3 NOD2 MSH2 ESR1 CTNNB1
4 mismatched DNA binding GO:0030983 9.4 MSH2 MLH1
5 nitric-oxide synthase regulator activity GO:0030235 9.32 ESR1 AKT1
6 enzyme binding GO:0019899 9.23 TP53 PTGS2 NOD2 MSH2 MLH1 ESR1
7 guanine/thymine mispair binding GO:0032137 9.16 MSH2 MLH1

Sources for Colonic Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....